Is lung cancer in the nonsmoker a different disease?

Chest

Volumn 126, Issue 2, 2004, Pages 326-329

  Mazzone, Peter J ^a   Mekhail, Tarek ^a   Arroliga, Alejandro C ^a,b  

^a Critical C ^*  (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZO[A]PYRENE; CARCINOGEN; CISPLATIN; CYTOCHROME P450 1A1; GEFITINIB; NITROSAMINE; TOBACCO SMOKE;

CANCER STAGING; CANCER SURVIVAL; CIGARETTE SMOKING; CLINICAL TRIAL; DEATH; DISEASE ASSOCIATION; DNA POLYMORPHISM; ECONOMIC ASPECT; EDITORIAL; EPIDEMIC; GENE AMPLIFICATION; HETEROZYGOSITY LOSS; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; PASSIVE SMOKING; PRIORITY JOURNAL; PROGNOSIS; SMOKING; SMOKING CESSATION; TOBACCO;

EID: 4143070315     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.126.2.326     Document Type: Editorial

References (28)

1. Annual smoking-attributable mortality, years of potential life lost, and economic cost. United States, 1995-1999. MMWR Morb Mortal Wkly Rep 2002; 251:300-303
2. Schroeder SA. Tobacco control in the wake of the 1998 master settlement agreement. N Engl J Med 2004; 350:293-301
3. Kuper H, Boffetta P, Adami HO. Tobacco use and cancer causation: association by tumour type. J Intern Med 2002; 252:206-224
4. Doll R, Hill AB. Smoking and carcinoma of the lung: preliminary report. BMJ 1950; 2:739-748
5. Doll R, Hill AB. The mortality of doctors in relation to their smoking habits: a preliminary report. BMJ 1952; 1:1451-1455
6. Yang P, Cerhan JR, Vierkant RA, et al. Adenocarcinoma of the lung is strongly associated with cigarette smoking: further evidence from a prospective study of women. Am J Epidemiol 2002; 156:1114-1122
7. Fry WA, Phillips JL, Menck HR. Ten-year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer data base report. Cancer 1999; 86:1867-1876
8. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 2002; 122:1037-1057
9. Buccheri G, Ferrigno D. Prognostic factors in lung cancer: tables and comments. Eur Respir J 1994; 7:1350-1364
10. Sorensen JB, Badsberg JH, Olsen J. Prognostic factors in inoperable adenocarcinoma of the lung: a multivariate regression analysis of 259 patients. Cancer Res 1989; 49:5748-5754
11. Grover FL, Piantadosi S. Recurrence and survival following resection of bronchioloalveolar carcinoma of the lung: the Lung Cancer Study Group experience. Ann Surg 1989; 209:779-790
12. Tammemagi CM, Neslund-Dudas C, Simoff M, et al. Smoking and lung cancer survival: the role of comorbidity and treatment. Chest 2004; 125:27-37
13. Goto I, Yoneda S, Yamamoto M, et al. Prognostic significance of germ line polymorphisms of the CYP1A1 and glutathione S-transferase genes in patients with non-small cell lung cancer. Cancer Res 1996; 56:3725-3730
14. Sanchez-Cespedes M, Ahrendt SA, Piantadosi S, et al. Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers. Cancer Res 2001; 61:1309-1313
15. Wong MP, Fung LF, Wang E, et al. Chromosomal aberrations of primary lung adenocarcinomas in nonsmokers. Cancer 2003; 97:1263-1270
16. Wistuba II, Lam S, Behrens C, et al. Molecular damage in the bronchial epithelium of current and former smokers. J Natl Cancer Inst 1997; 89:1366-1373
17. Virmani AK, Fong KM, Kodagoda D, et al. Allelotyping demonstrates common and distinct patterns of chromosomal loss in human lung cancer types. Genes Chromosomes Cancer 1998; 21:308-319
18. Kok K, Osinga J, Carritt B, et al. Deletion of a DNA sequence at the chromosomal region 3p21 in all major types of lung cancer. Nature 1987; 330:578-581
19. Wistuba II, Behrens C, Virmani AK, et al. High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res 2000; 60:1949-1960
20. Naylor SL, Johnson BE, Minna JD, et al. Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer. Nature 1987; 329:451-454
21. Kim DH, Kim JS, Ji YI, et al. Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer. Cancer Res 2003; 63:3743-3746
22. Hashimoto T, Tokuchi Y, Hayashi M, et al. Different subtypes of human lung adenocarcinoma caused by different etiological factors: evidence from p53 mutational spectra. Am J Pathol 2000; 157:2133-2141
23. Hainaut P, Pfeifer GP. Patterns of p53 G->T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. Carcinogenesis 2001; 22: 367-374
24. Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 2001; 19(18 Suppl):32S-40S
25. Ahrendt SA, Decker PA, Alawi EA, et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 2001; 92:1525-1530
26. Rusch WV, Reuter VE, Kris MG, et al. Ras oncogene point mutation: an infrequent event in bronchioloalveolar cancer. J Thorac Cardiovasc Surg 1992; 104:1465-1469
27. Singh B, Reddy PG, Goberdhan A, et al. p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas. Genes Dev 2002; 16:984-993
28. Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004; 22:1103-1109